Colorectal cancer (CRC) remains a leading cause of cancer-related mortality despite efforts
to improve standard interventions. As CRC patients can benefit from immunotherapeutic …

Despite the availability of various treatment options, colorectal cancer (CRC) remains a
significant contributor to cancer-related mortality. Current standard-of-care interventions …

Renal cell carcinoma (RCC) is the deadliest form of urological cancer and is projected to be
the fourth most common neoplasm in the USA in males by 2040. In addition to the current …

The Gram-positive bacterium Listeria monocytogenes (Lm) is an emerging platform for
cancer immunotherapy. To date, over 30 clinical trials have been initiated testing Lm cancer …

Simple Summary Despite their potential and promising anti-tumor efficacy, previously
developed cancer vaccines targeting different tumor-associated antigens for colorectal …

Targeting tumor-associated angiogenesis is currently at the forefront of renal cell carcinoma
(RCC) therapy, with sunitinib and bevacizumab leading to increased survival in patients with …

Background In the past few decades, subcutaneous tumors have been used extensively in
vivo studies to test the therapeutic efficacy of several forms of anti-cancer agents including …

Cancer immunoprevention is an emerging field that holds much promise. Within the past 20
years, prophylactic vaccines have been implemented on the population level for the …

Background Agents that modulate the tumor microenvironment (TME) to promote anti-tumor
effects are desirable for the therapy of solid tumors. Recombinant Listeria-monocytogenes …

Abstract Purpose: Listeria monocytogenes (Lm)-based vaccines stimulate both innate and
adaptive immunity. ANZ-100 is a live-attenuated Lm strain (Lm Δ actA/Δ inlB). Uptake by …